GM Advisory Group LLC Has $1.12 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

GM Advisory Group LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,153 shares of the medical research company’s stock after selling 166 shares during the quarter. GM Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $1,120,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth about $26,000. Barrett & Company Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $28,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $28,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Finally, Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TMO shares. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 31st. Bank of America decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Raymond James reissued an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $653.23.

Thermo Fisher Scientific Stock Up 0.4 %

Shares of NYSE TMO opened at $521.42 on Wednesday. The company has a market capitalization of $196.71 billion, a P/E ratio of 31.54, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company’s 50 day moving average price is $547.72 and its 200-day moving average price is $557.48.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

Insider Activity at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.